Drupal.behaviors.print = function(context) {window.print();window.close();}>
Rosetta Genomics Stock Surges on Lung Cancer Dx Findings
January 13, 2010
Rosetta Genomics Stock Surges on Lung Cancer Dx Findings
By a GenomeWeb staff reporter
A new study from Johns Hopkins and Rosetta researchers finds the miRview NSCLC test to be effective.
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Rosetta Genomics to Raise $4.5M Through Direct Offering
January 14, 2010 / GenomeWeb Daily News
Rosetta Genomics' 2012 Revenues Nearly Double
March 25, 2013 / GenomeWeb Daily News
With Second-Gen Test Menu in Place, Rosetta Genomics Sets Sights on Third-Gen Pipeline
September 16, 2010 / Gene Silencing News
Rosetta Genomics Completes $4.5M Financing
January 20, 2010 / GenomeWeb Daily News
Rosetta Genomics Picks Up Pacific Rim Distributor
October 22, 2009 / GenomeWeb Daily News